# A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting

> **NCT03160040** · — · COMPLETED · sponsor: **Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)** · enrollment: 71 (actual)

## Conditions studied

- Gram-Negative Bacterial Infections

## Interventions

- **DRUG:** Minocycline IV

## Key facts

- **NCT ID:** NCT03160040
- **Lead sponsor:** Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-11
- **Primary completion:** 2018-05-01
- **Final completion:** 2018-05-01
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2023-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03160040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03160040, "A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03160040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*